Sin conexión a internet: se muestra la versión guardada de la página.

Arrowhead Pharmac…

USUSD
← Al Screener

Arrowhead Pharmaceuticals Inc (LSE:0HI3) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la Empresa

Sitio Web
arrowheadpharma.com
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Sede Central
Pasadena, United States
Consejero Delegado
Christopher R. Anzalone
Empleados
711
Fundada
2004
Acciones en Circulación
141.25 M a 2026-07-30
Capital Flotante
122.45 M
Capitalización Bursátil
9.22 mil M USD
Insiders
3.66%
Inversores Institucionales
85.47%
Industria (SIC)
Pharmaceutical Preparations
ISIN
US04280A1007
LEI
549300O3CSB8T7OZ3D66
FCF
−75.1 M USD
Deuda
181 M USD
Resultados y FCF — para los 12 meses hasta 30.06.2026 (el último informe de la empresa).
NAV
3.30 USD · P/NAV 20.0
Fecha del Balance30.06.2026
Activos2.11 mil M USD
− Pasivos1.65 mil M USD
= Patrimonio Total466 M USD
− Participaciones No Dominantes512 mil USD
= NAV (patrimonio de los accionistas de la empresa)466 M USD
− Activos Intangibles5.59 M USD
= NAV Tangible460 M USD
Acciones141 135 000
NAV por Acción3.30 USD
NAV Tangible por Acción3.26 USD
Precio de la Acción (0HI3)65.8200 USD
P/NAV19.95
Historial del NAV
Fecha del BalanceNAVNAV por Acción
30.06.2026466 M USD3.30 USD
31.03.2026614 M USD4.37 USD
31.12.2025568 M USD4.14 USD
30.09.2025466 M USD3.43 USD
30.06.2025522 M USD3.78 USD
31.03.2025683 M USD4.95 USD
31.12.202452.6 M USD0.42 USD
30.09.2024185 M USD1.49 USD
Descripción

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

anuncio

Bolsas y Tickers

BolsaTickerMonedaPrecioTipo
US USA StocksARWR principalUSD58.5 +0.22%acciones ordinarias
LSE London Stock Exchange0HI3 IOBUSD65.82 +0.00%acciones ordinarias

Precio en 3 Meses

día alcista día bajistaPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Principales Accionistas

TitularParticipaciónAccionesFecha del Informe
Blackrock Inc.10.53%14.83 M2026-06-30
Avoro Capital Advisors L…8.06%11.36 M2026-06-30
FMR, LLC5.71%8.04 M2026-06-30
Vanguard Portfolio Manag…4.51%6.35 M2026-06-30
Vanguard Capital Managem…4.34%6.11 M2026-06-30
State Street Corporation4.04%5.69 M2026-06-30
iShares Trust-iShares Co…3.5%4.93 M2026-08-31
VANGUARD INDEX FUNDS-Van…3.01%4.25 M2026-06-30
NORGES BANK2.77%3.9 M2026-06-30
Invesco Ltd.2.76%3.88 M2026-06-30
ANZALONE CHRISTOPHER RIC…≈2.69%3.79 M2026-01-02
Geode Capital Management…2.51%3.53 M2026-06-30
Fred Alger Management, L…2.34%3.3 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.18%3.07 M2026-06-30
Fidelity Mt. Vernon Stre…1.81%2.55 M2026-07-31
Invesco Exchange-Traded…1.27%1.79 M2026-08-31
VANGUARD INDEX FUNDS-Van…1.26%1.77 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%1.61 M2026-06-30
SPDR SERIES TRUST-State…1.05%1.48 M2026-08-31
SPDR S&P MIDCAP 400 ETF…0.73%1.03 M2026-08-31
iShares Trust-iShares Bi…0.69%968 7382026-07-31
O'BRIEN PATRICK C (Chief…≈0.39%547 4082026-01-06
MYSZKOWSKI KENNETH ALLEN…≈0.32%455 4332025-01-07
HAMILTON JAMES C (Office…≈0.16%226 9582026-04-23
APEL DANIEL JOSEPH (Chie…≈0.12%162 9052026-04-22
GIVEN DOUGLAS BRUCE (Dir…≈0.09%124 1672024-12-17
PERRY MICHAEL S (Directo…≈0.08%111 4592026-08-18
FERRARI MAURO (Director)≈0.05%69 0532025-12-26
WADDILL WILLIAM D (Direc…≈0.04%56 5632025-12-19
LU HONGBO B (Director)≈0.04%52 0122026-05-12